{{Medical}}

'''电脉冲化疗'''是一种通过施加局部电脉冲，增加[[细胞|细胞]]通透性，将通常情况下无法进入细胞内部的药物送入细胞内，从而达到杀死癌细胞目的的治疗癌症的疗法<ref name="refname1"/><ref name="refname2"/>。配合[[博莱霉素|博莱霉素]]和[[顺铂|顺铂]]使用电脉冲化疗治疗皮内和皮下[[肿瘤|肿瘤]]的研究已经进入临床阶段。<ref name="refname3"/><ref name="refname4"/><ref name="refname5"/><ref name="refname6"/><ref name="refname7"/><ref name="refname8"/><ref name="refname9"/><ref name="refname10"/><ref name="refname11"/><ref name="refname12"/>第一次伯莱霉素电脉冲化疗于1991年在法国Gustave Roussy研究所实现<ref name="refname13"/>，第一次顺铂电脉冲化疗则于1995年在斯洛文尼亚卢布尔雅那肿瘤研究所实现<ref name="refname14"/>。其后，来自全球多个国家（爱尔兰、澳洲、奥地利、比利时、保加利亚、丹麦、德国、法国、美国、墨西哥、尼加瓜拉、波兰、葡萄牙、日本、瑞士、斯洛文尼亚、西班牙、希腊、匈牙利、意大利、英国）的4000多名患者接受了电脉冲化疗。最近，为了治疗体内肿瘤，开发了通过[[外科手术|外科手术]]、[[内窥镜|内窥镜]]、[[皮下穿刺|皮下穿刺]]等方法到达患处的新的电脉冲化疗方法。<ref name="refname15"/><ref name="refname16"/>

==物理原理==

当细胞暴露在足够强的[[电场|电场]]中时，[[跨膜电位|跨膜电位]]（[[细胞膜|细胞膜]]内外的[[电势差|电势差]]）将会增加，这会引发细胞膜结构重排<ref name="refname17"/><ref name="refname18"/><ref name="refname19"/><ref name="refname20"/><ref name="refname21"/><ref name="refname22"/>，从而导致细胞膜通透性增加，进而允许通常无法穿过细胞膜的分子进入细胞<ref name="refname13"/><ref name="refname23"/><ref name="refname24"/>。这一被称为{{link-en|电穿孔|electroporation}}或{{link-en|电通透|electropermeabilization}}的现象，正被广泛应用到抗肿瘤治疗中。这种治疗方案就是广为熟知的电脉冲化疗。电脉冲化疗只采用短暂但强劲的单级直流电，尽管在体外培养的细胞和[[细菌|细菌]]中可以用电场强度随时间衰减的脉冲。在生物体内完整组织中，脉冲的电场强度依不同组织和电极的形状和位置而不同。在一般的肿瘤治疗中，电脉冲强度需要在肿瘤范围内达到400V/cm。通常每次连续施加8个持续100微秒<ref name="refname25"/>的脉冲。在最初的试验中，施加脉冲的频率为1Hz，而现在通常采用5000Hz，因为这可以大大降低患者的不适感和治疗的持续时间<ref name="refname26"/><ref name="refname27"/>。而在治疗靠近[[心脏|心脏]]的肿瘤时，脉冲应和心肌的[[动作电位|绝对不应期]]同步，从而尽可能降低电脉冲影响心脏正常功能的可能性。<ref name="refname28"/>

==治疗说明==

电脉冲治疗首先需要对全身或局部引入不通透或低通透的[[细胞毒性|细胞毒素药物]]。然后，当肿瘤区域药物浓度达到峰值时直接对该区域施加脉冲电场<ref name="refname12"/>。脉冲电场可以在细胞膜上产生[[纳米|纳米]]级缺陷，从而方便药物进入细胞。在施加电场期间以及电场消失后的一段时间内，药物分子可以自由扩散进入细胞质，从而实现抗肿瘤效果。如果药物浓度足够，可以通过在不同的地方插入电极和施加多次电场来治疗整个肿瘤。<ref name="refname25"/>如果首次治疗时因肿瘤太大而无法对整个肿瘤施加电脉冲化疗，也可以在几周或几个月后继续治疗。

==疗效和相关性==

一些二期临床实验证明，使用博莱霉素和顺铂的电脉冲化疗对皮内或皮下肉瘤的[[客观应答率|客观应答率]]超过80%。<ref name="refname4"/><ref name="refname29"/>电脉冲化疗在缩小皮肤肿瘤和皮下肿瘤的大小上比化疗更快更有效。电脉冲化疗对[[黑色素瘤|黑色素瘤]]、[[Kaposi肉瘤|Kaposi肉瘤]]、[[鳞状细胞癌|鳞状细胞癌]]、[[基底细胞癌|基底细胞癌]]、[[腺癌|腺癌]]、[[乳腺癌|乳腺癌]]均有疗效。<ref name="refname4"/><ref name="refname5"/><ref name="refname6"/><ref name="refname7"/><ref name="refname9"/><ref name="refname10"/><ref name="refname30"/>初步表明也很有希望可以利用电脉冲疗法治疗内部肿瘤（例如肝转移肿瘤）。

==安全性==

电脉冲化疗所使用的药物浓度比普通化疗所使用的更低，因此没有常规化疗所引起的不良反应。适当的麻醉可以减轻电脉冲引起的不适症状，从而可以把疼痛感控制在病人可以接受的范围内。除去电脉冲引起的疼痛以外，脉冲期间的肌肉收缩是患者唯一的不适。<ref name="refname4"/><ref name="refname31"/>脉冲同时会引起短暂的缺血。在治疗区域内，正常组织内的血液循环会被打断几分钟<ref name="refname32"/><ref name="refname33"/>，但是由于时间短暂，所以并不会产生缺血反应；相反地，肿瘤组织内部的缺血时间会更长，从而对抑制肿瘤也有一定帮助。在一项以建立欧洲电脉冲化疗标准手术程序为目的的医疗实验中，大部分接受调查患者表示如果需要，愿意再次接受电脉冲化疗<ref name="refname4"/>，因此可以推断电脉冲化疗并不特别令人痛苦或者紧张。<ref name="refname4"/><ref name="refname34"/>

==兽医应用==

电脉冲化疗同样可以应用于[[犬|犬类]]、[[猫|猫]]和[[马|马]]的肿瘤治疗。巴西、法国、意大利、爱尔兰、斯洛文尼亚、英国及台灣的一些医疗中心可以提供针对各种肿瘤的治疗。<ref name="refname34"/>

==评论==
电脉冲化疗在多个欧盟国家（波兰、丹麦、德国、葡萄牙、斯洛文尼亚、希腊、意大利和英国）都已经获得认可和医疗补贴。意大利Carpy Igea, s.r.l.生产的Cliniporator仪被认证为医疗器具并和欧洲电脉冲化疗标准手术程序一起向市场推广。<ref name="refname4"/>

==参考资料==
{{Reflist|
refs=
<ref name="refname1"> Mir LM, Orlowski S, Belehradek J, Paoletti C (1991). "Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses". Eur. J. Cancer 27 (1): 68–72. PMID 1707289.</ref>
<ref name="refname2"> Sersa G, Cemazar M, Miklavcic D (August 1995). "Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice". Cancer Res. 55 (15): 3450–5. PMID 7614485.</ref>
<ref name="refname3"> Gehl, J. & Geertsen, P.F. Palliation of haemorrhaging and ulcerated cutaneous tumours using electrochemotherapy. Eur J Cancer Suppl 4, 35-37 (2006).</ref>
<ref name="refname4"> Marty, M. et al. Electrochemotherapy - An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer Suppl 4, 3-13 (2006).</ref>
<ref name="refname5"> Larkin JO, Collins CG, Aarons S, et al. (March 2007). "Electrochemotherapy: aspects of preclinical development and early clinical experience". Ann. Surg. 245 (3): 469–79. doi:10.1097/01.sla.0000250419.36053.33. PMC 1877027. PMID 17435555.</ref>
<ref name="refname6"> Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M (February 2008). "Electrochemotherapy in treatment of tumours". Eur J Surg Oncol 34 (2): 232–40. doi:10.1016/j.ejso.2007.05.016. PMID 17614247.</ref>
<ref name="refname7"> M?ller MG, Salwa S, Soden DM, O'Sullivan GC (November 2009). "Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma". Expert Rev Anticancer Ther 9 (11): 1611–30. doi:10.1586/era.09.129. PMID 19895245.</ref>
<ref name="refname8"> Campana, L.G. et al. Electrochemotherapy: clinical outcome and predictive factors from a single institution experience on 50 melanoma patients. Ann Surg Oncol 17, S106-S106 (2010).</ref>
<ref name="refname9"> Testori A, Tosti G, Martinoli C, et al. (2010). "Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach". Dermatol Ther 23 (6): 651–61. doi:10.1111/j.1529-8019.2010.01370.x. PMID 21054709.</ref>
<ref name="refname10"> Hampton T (February 2011). "Electric pulses help with chemotherapy, may open new paths for other agents". JAMA 305 (6): 549–51. doi:10.1001/jama.2011.92. PMID 21304073.</ref>
<ref name="refname11"> Mu?oz Madero V, Ortega Pérez G (January 2011). "Electrochemotherapy for treatment of skin and soft tissue tumours. Update and definition of its role in multimodal therapy". Clin Transl Oncol 13 (1): 18–24. PMID 21239351.</ref>
<ref name="refname12"> Sersa G, Miklavcic D (2008). "Electrochemotherapy of tumours". J Vis Exp (22). doi:10.3791/1038. PMC 2762922. PMID 19229171.</ref>
<ref name="refname13"> Mir LM, Belehradek M, Domenge C, et al. (1991). "Electrochemotherapy, a new antitumor treatment: first clinical trial (in French). C. R. Acad. Sci. III, Sci. Vie 313 (13): 613–8. PMID 1723647.</ref>
<ref name="refname14"> Rudolf, Z. et al. Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients. Radiol Oncol 29, 229-35 (1995).</ref>
<ref name="refname15"> Soden DM, Larkin JO, Collins CG, et al. (February 2006). "Successful application of targeted electrochemotherapy using novel flexible electrodes and low dose bleomycin to solid tumours". Cancer Lett. 232 (2): 300–10. doi:10.1016/j.canlet.2005.03.057. PMID 15964138.</ref>
<ref name="refname16"> Miklavcic, D. et al. Towards treatment planning and treatment of deep-seated solid tumors by electrochemotherapy. BioMed Eng OnLine 9, 10 (2010).</ref>
<ref name="refname17"> Weaver, J.C. & Chizmadzhev, Y.A. Theory of electroporation: A review. Bioelectrochemistry Bioenerg 41, 135-160 (1996).</ref>
<ref name="refname18"> Kotnik, T., Bobanovic, F. & Miklavcic, D. Sensitivity of transmembrane voltage induced by applied electric fields - a theoretical analysis. Bioelectrochemistry Bioenerg 43, 285-291 (1997).</ref>
<ref name="refname19"> Weaver, J.C. Electroporation of cells and tissues. IEEE Trans Plasma Sci 28, 24–33 (2000).</ref>
<ref name="refname20"> Chen C, Smye SW, Robinson MP, Evans JA (March 2006). "Membrane electroporation theories: a review". Med Biol Eng Comput 44 (1-2): 5–14. doi:10.1007/s11517-005-0020-2. PMID 16929916.</ref>
<ref name="refname21"> Puc M, Kotnik T, Mir LM, Miklavcic D (August 2003). "Quantitative model of small molecules uptake after in vitro cell electropermeabilization". Bioelectrochemistry 60 (1-2): 1–10. PMID 12893304.</ref>
<ref name="refname22"> Puc M, Corovi? S, Flisar K, Petkovsek M, Nastran J, Miklavcic D (September 2004). "Techniques of signal generation required for electropermeabilization. Survey of electropermeabilization devices". Bioelectrochemistry 64 (2): 113–24. doi:10.1016/j.bioelechem.2004.04.001. PMID 15296784.</ref>
<ref name="refname23"> Cemazar M, Sersa G (December 2007). "Electrotransfer of therapeutic molecules into tissues". Curr. Opin. Mol. Ther. 9 (6): 554–62. PMID 18041666.</ref>
<ref name="refname24"> Sersa G, Stabuc B, Cemazar M, Jancar B, Miklavcic D, Rudolf Z (July 1998). "Electrochemotherapy with cisplatin: potentiation of local cisplatin antitumour effectiveness by application of electric pulses in cancer patients". Eur. J. Cancer 34 (8): 1213–8. PMID 9849482.</ref>
<ref name="refname25"> Zupanic, A., Corovic, S. & Miklavcic, D. Optimization of electrode position and electric pulse amplitude in electrochemotherapy. Radiol Oncol 42, 93-101 (2008).</ref>
<ref name="refname26"> Pucihar G, Mir LM, Miklavcic D (September 2002). "The effect of pulse repetition frequency on the uptake into electropermeabilized cells in vitro with possible applications in electrochemotherapy". Bioelectrochemistry 57 (2): 167–72. PMID 12160614.</ref>
<ref name="refname27"> Zupanic A, Ribaric S, Miklavcic D (2007). "Increasing the repetition frequency of electric pulse delivery reduces unpleasant sensations that occur in electrochemotherapy". Neoplasma 54 (3): 246–50. PMID 17447858.</ref>
<ref name="refname28"> Mali B, Jarm T, Corovic S, et al. (August 2008). "The effect of electroporation pulses on functioning of the heart". Med Biol Eng Comput 46 (8): 745–57. doi:10.1007/s11517-008-0346-7. PMC 2491703. PMID 18415132.</ref>
<ref name="refname29"> Sersa, G. The state-of-the-art of electrochemotherapy before the ESOPE study; advantages and clinical uses. Eur J Cancer Suppl 4, 52-59 (2006).</ref>
<ref name="refname30"> Heller R, Gilbert R, Jaroszeski MJ (January 1999). "Clinical applications of electrochemotherapy". Adv. Drug Deliv. Rev. 35 (1): 119–129. PMID 10837693.</ref>
<ref name="refname31"> Sersa G, Jarm T, Kotnik T, et al. (January 2008). "Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma". Br. J. Cancer 98 (2): 388–98. doi:10.1038/sj.bjc.6604168. PMC 2361464. PMID 18182988.</ref>
<ref name="refname32"> Jarm T, Cemazar M, Miklavcic D, Sersa G (May 2010). "Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases". Expert Rev Anticancer Ther 10 (5): 729–46. doi:10.1586/era.10.43. PMID 20470005. </ref>
<ref name="refname33"> Cemazar M, Tamzali Y, Sersa G, et al. (2008). "Electrochemotherapy in veterinary oncology". J. Vet. Intern. Med. 22 (4): 826–31. doi:10.1111/j.1939-1676.2008.0117.x. PMID 18537879.</ref>
<ref name="refname34"> Mir, L.M. et al. Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. Eur J Cancer Suppl 4, 14-25 (2006).</ref>
}}

==参考==
* [[不良反应_(医学)|不良反应 (医学)]]
* [[病人安全|病人安全]]
* [[靶向藥物|靶向藥物]]
* [[化学疗法|化学疗法]]


[[Category:抗肿瘤药|]]
[[Category:肿瘤学|Category:肿瘤学]]
[[Category:癌症治療|Category:癌症治療]]